Use your browser's back button to choose another title or click here for a New Search.

How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access




Bookmark and Share


Special Supplement to Journal of Substance Abuse Treatment, "A Decade of Research by the National Drug Abuse Treatment Clinical Trials Network."

From Research to the Real World: Buprenorphine in the Decade of the Clinical Trials Network.

Journal of Substance Abuse Treatment 2010;38(suppl 1):S53-S60. [doi: 10.1016/j.jsat.2010.01.009]

Walter Ling, MD (Integrated Substance Abuse Programs(ISAP), UCLA, PR Node), Petra Jacobs, MD (NIDA Center for the Clinical Trials Network (CCTN)), Maureen Hillhouse, PhD (ISAP, UCLA, PR Node), Albert Hasson, MSW (ISAP, UCLA, PR Node), Christie Thomas, MPH (ISAP, UCLA, PR Node), Thomas E. Freese, PhD (ISAP, UCLA, PR Node), Steven Sparenborg, PhD (NIDA CCTN), Dennis McCarty, PhD (Oregon Health & Science University, OR/HI Node), Roger D. Weiss, MD (Harvard Medical School, NNE Node), Andrew J. Saxon, MD (VA Puget Sound Health Care System, PN Node), Allan J. Cohen, MA, MFT (Bay Area Addiction Research & Treatment, PR Node), Michele M. Straus, RPh, MS (NIDA CCTN), Gregory S. Brigham, PhD (Maryhaven, Inc., OV Node), David S. Liu, MD (NIDA CCTN), Paul McLaughlin, MA (Hartford Dispensary, NE Node), Betty Tai, PhD (NIDA CCTN).

The National Institute on Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical Trials Network (CTN) in 1999 to bring researchers and treatment providers together to develop a clinically relevant research agenda. Initial CTN efforts addressed the use of buprenorphine, a mu-opioid partial agonist, as treatment for opioid dependence. Strong evidence of buprenorphine's therpeutic efficacy was demonstrated in cilnical trials involving several thousand opioid-dependent participants, and in 2002, the Food and Drug Administration approved buprenorphine for the treatment of opioid dependence. With the advent of a sublingual tablet containing both buprenorphine and naloxone to mitigate abuse and diversion (Suboxone), buprenorphine appeared poised to be the first-line treatment for opioid addiction. Notwithstanding its many attributes, certain implementation barriers remained to be addressed in CTN studies, and these efforts have brought a body of knowledge on buprenorphine to frontline clinicians. The purpose of this article is to review CTN-based buprenorphine research (four completed protocols and two ongoing ones) and related efforts to overcome challenges to the implementation of buprenorphine therapy in mainstream practice. Furthermore, this article explores current issues and future challenges that may require additional CTN efforts. CTN researchers and CTPs are currently engaged in a consensus-building process to develop a clinical trial to assess the safety and utility of buprenorphine given concurrently with naltrexone for the treatment of opioid and cocaine addiction, with the hope that buprenorphine will next become a successful part of the armamentarium for cocaine addiction. (Article (Peer-Reviewed), PDF, English, 2010)

Keywords: Adoption of interventions | Blending Team Products | Buprenorphine/Naloxone | Cocaine | Community health services | CTN 10-year anniversary | Dissemination | Heroin | Opioid dependence | Opioid detoxification | Pharmacological therapy | Pre scription-type opiates | Suboxone | Journal of Substance Abuse Treatment (journal)

Document No: 431, PMID: 20307796, PMCID: PMC2853172.

Submitted by CTN Dissemination Librarians, 3/22/2010


Brigham, Gregory S. www
Cohen, Allan J. www
Freese, Thomas E. www
Hasson, Albert www
Hillhouse, Maureen www
Jacobs, Petra www
Ling, Walter www
McCarty, Dennis www
McLaughlin, Paul www
Saxon, Andrew J. www
Sparenborg, Steven www
Straus, Michele M. www
Tai, Betty www
Thomas, Christie www
Weiss, Roger D. www
NIDA-CTN-0001 search www
NIDA-CTN-0002 search www
NIDA-CTN-0003 search www
NIDA-CTN-0010 search www
NIDA-CTN-0027 search www
NIDA-CTN-0030 search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 6/2011 --